68195-63-1

Basic information

• Product Name: Edaravone
• Synonyms: 3,3'',5'-trimethyl-1,1'',2'-triphenyl- 1H,1''H-[4,4':4',4''-terpyrazole]- 3',5,5''(2'H,4H,4''H)-trione;5,5',5''-Trimethyl-2,2',2''-triphenyl-[4,4':4',4''-ter-4H-pyrazole]-3,3',3''(2H,2'H,2''H)-trione
• CAS NO: 68195-63-1
• Molecular Formula: C₃₀H₂₆N₆O₃
• Molecular Weight: 518.56584
• EINECS: -0
• Mol File: 68195-63-1.mol
• Article Data: 3

Chemical Properties

• Melting Point: 200 °C (decomp)(Solv: ethanol (64-17-5))
• Boiling Point: 770.6±60.0 °C(Predicted)
• Appearance: /
• Density: 1.34±0.1 g/cm3(Predicted)
• PKA: 2.15±0.70(Predicted)
• CAS DataBase Reference: Edaravone(CAS DataBase Reference)
• NIST Chemistry Reference: Edaravone(68195-63-1)
• EPA Substance Registry System: Edaravone(68195-63-1)

Safety Data

• Hazardous Substances Data: 68195-63-1(Hazardous Substances Data)

Usage

Description

Edaravone is a medication with neuroprotective properties, primarily used for the treatment of acute cerebral infarction and amyotrophic lateral sclerosis (ALS). It functions by eliminating free radicals and reducing oxidative stress, which are significant factors contributing to neuronal damage.

Uses

Used in Pharmaceutical Industry:
Edaravone is used as an intravenous medication for the treatment of acute cerebral infarction, aiming to facilitate recovery following a stroke by reducing neuronal damage and oxidative stress.
Additionally, Edaravone is used as an oral medication for the treatment of amyotrophic lateral sclerosis (ALS), where it helps to slow the progression of the disease by protecting neurons from oxidative stress and free radical damage.

Upstream product

• 19735-89-8 3-methyl-1-phenylpyrazolin-5(4H)-one 
• 89-25-8 edaravone 
• 74451-57-3 (E)-5,5'-dimethyl-2,2'-diphenyl-2H,2'H-[4,4']bipyrazolylidene-3,3'-dione 

Relevant articles and documents

Accidental synthesis of a trimer of pyrazolone and comparison of its antioxidant activity: an investigatory report

Abstract: Untargeted synthesis leading to the formation of a significant product is a common practice and has been successfully achieved after holistic characterization of the accidentally formed molecule of the trimer of pyrazolone. Its significance was further explored in the pharmaceutical field emphasizing the need for the synthesis and validating the newly established pathways for its synthesis. It was known that pyrazolone exhibit a plethora of applications ranging from catalysis, decolourisation of dyes and metallurgical extractions. Paramount importance has been attributed to pyrazolones in recent years for their broad-spectrum biological activities manifested in their anti-inflammatory, analgesic, anticancer and anti-tubercular functions. In the ongoing research 4,4-Bis-(3-methyl-phenyl-pyrozolin-5-on-4-yl)-3-methyl-1-phenyl-pyrzolin-5-one was synthesized economically and efficiently via a novel one-step bio-catalytic pathway using laccase as a catalyst. To validate the utility of our accidental discovery, we have also calculated its antioxidant activity against ascorbic acid as a standard compound. DPPH and ABTS have been used to study the scavenging of free radicals in-vitro. This is the first report of the enzyme driven synthesis of trimeric form of pyrazolone. These results will emphasise the utilization of pyrazolone trimers as eco-friendly compounds which exhibit a promising natural antioxidant property in physiological environments. Graphic abstract: An investigatory report is being presented featuring a novel eco-friendly pathway for the synthesis of trimeric of pyrazolone i.e., 4,4-Bis-(3-methyl-phenyl-pyrozolin-5-on-4-yl)-3-methyl-1-phenyl-pyrzolin-5-one. The trimeric form of the molecule possesses spiked antioxidant properties verified by DPPH and ABTS assays. Thus, this work opens new frontiers for further research in this direction.[Figure not available: see fulltext.]

Free Radical Reactions of N-Heterocyclic Compounds. XI. Reaction of 3-Methyl-pyrazolin-5-ones with Phenoxy Radicals

Pyrazolin-5-ones (3a-i) were oxidized with 2,4,6-trisubstituted phenoxy radicals (2a-d) to the corresponding radicals (4a-i), which dimerised or combined with phenoxy radical (2a) depending on the R1- and R4-substituents in (3).In th